Your AI-Trained Oncology Knowledge Connection!

The Evolving Treatment Landscape of Small Cell Lung Cancer : Episode 14

Video

August 11, 2022

Investigational Agents in SCLC in the Second Line Setting and Beyond

Author(s):

Charu Aggarwal, MD, MPH,Taofeek K. Owonikoko, MD, PhD

Taofeek Owonikoko, MD, PhD, highlights investigational agents and ongoing clinical trials in SCLC he looks forward to.

EP: 1.Overview of SCLC and Importance of Early Diagnosis

EP: 2.Use of the TNM Staging System in SCLC

EP: 3.Progress in the Treatment and Management of SCLC

EP: 4.Patient Profile 1: A 68-Year-Old Male with SCLC and Brain Metastases

EP: 5.Frontline Therapy for SCLC: The CASPIAN Trial of Durvalumab + Chemotherapy

EP: 6.Management of Adverse Events Associated with Durvalumab + Chemotherapy

EP: 7.IMpower 133 Trial and Patient Selection for Durvalumab + Chemotherapy vs Atezolizumab + Chemotherapy

EP: 8.Ongoing Trials and Real-World Studies in Frontline SCLC

EP: 9.Patient Profile 2: A 60-Year-Old Man with SCLC Progressing on First-Line Therapy

EP: 10.Second Line Treatment Options in SCLC and Selecting the Appropriate Therapy

EP: 11.Lurbinectedin for SCLC Treatment in the Second-Line Setting

EP: 12.Patient Profile 3: A 70-Year-Old Man with SCLC Receiving Chemotherapy in the Second-Line Setting

EP: 13.Choosing the Appropriate Treatment in the Second Line Setting in SCLC

Now Viewing

EP: 14.Investigational Agents in SCLC in the Second Line Setting and Beyond

EP: 15.Clinical Practice Pearls and the Future of SCLC

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All

Video

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

Apr 17th 2025 - May 23rd 2025

online-activity

Video

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

Apr 17th 2025 - May 23rd 2025

online-activity

Video

18th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies

Apr 8th 2025 - May 14th 2025

online-activity

Latest Conference Coverage

Overview of iMMagine-1 Trial: Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of R/R MM

Application of Real-World Evidence in Selecting CAR T in R/R MM

Addition of Daratumumab to Lenalidomide Maintenance Boosts MRD-Negative Conversions in Myeloma Following ASCT

Apalutamide Boosts 24-Month OS in Real-World Population With Metastatic Castration-Sensitive Prostate Cancer

View More Latest Conference Coverage

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Privacy

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

Investigational Agents in SCLC in the Second Line Setting and Beyond

EP: 1.Overview of SCLC and Importance of Early Diagnosis

EP: 2.Use of the TNM Staging System in SCLC

EP: 3.Progress in the Treatment and Management of SCLC

EP: 4.Patient Profile 1: A 68-Year-Old Male with SCLC and Brain Metastases

EP: 5.Frontline Therapy for SCLC: The CASPIAN Trial of Durvalumab + Chemotherapy

EP: 6.Management of Adverse Events Associated with Durvalumab + Chemotherapy

EP: 7.IMpower 133 Trial and Patient Selection for Durvalumab + Chemotherapy vs Atezolizumab + Chemotherapy

EP: 8.Ongoing Trials and Real-World Studies in Frontline SCLC

EP: 9.Patient Profile 2: A 60-Year-Old Man with SCLC Progressing on First-Line Therapy

EP: 10.Second Line Treatment Options in SCLC and Selecting the Appropriate Therapy

EP: 11.Lurbinectedin for SCLC Treatment in the Second-Line Setting

EP: 12.Patient Profile 3: A 70-Year-Old Man with SCLC Receiving Chemotherapy in the Second-Line Setting

EP: 13.Choosing the Appropriate Treatment in the Second Line Setting in SCLC

EP: 14.Investigational Agents in SCLC in the Second Line Setting and Beyond

EP: 15.Clinical Practice Pearls and the Future of SCLC

Newsletter

Latest CME

18th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | Arkansas

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

18th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | Arkansas

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

18th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | Arkansas

Latest Conference Coverage